Compare Adaptive Biotechnologies Corp (ADPT) vs Virgin Galactic Holdings, Inc. (SPCE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Virgin Galactic Holdings, Inc. — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Virgin Galactic Holdings, Inc. trades at $2.64 (market cap $330.34M). The key difference: Adaptive Biotechnologies Corp is far larger — about 10.1× Virgin Galactic Holdings, Inc.'s market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Virgin Galactic Holdings, Inc. nearer its low. Which is the better fit depends on your goals.
| ADPT | SPCE | |
|---|---|---|
Market Cap | $3.33B | $330.34M |
Sector | Health | Industrials |
52-Week High | $22.37 | $7.52 |
52-Week Low | $10.24 | $2.17 |
Enterprise Value | $3.19B | $430.19M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Virgin Galactic (SPCE) trades at $2.57, down 4.81% today, reflecting persistent bearish technical signals and weak fundamentals. The company continues to report significant losses, with a net income margin of -19,781.3% in 2025 and negative cash flow from operations. Recent news highlights volatility tied to SpaceX IPO developments, with SPCE shares experiencing sharp swings. Analyst consensus is mixed, with 29% buy, 41% hold, and 29% sell ratings, indicating cautious sentiment amid ongoing financial challenges.
The outlook remains highly speculative, with investment opportunity hinging on future commercial spaceflight success, but risks are substantial. High cash burn, lack of profitability, and intense competition threaten shareholder value. Without near-term revenue growth or path to profitability, the stock faces significant downside risk despite trading near historical lows.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Virgin Galactic Holdings, Inc.
Virgin Galactic Holdings Inc. develops space vehicles. The Company designs exploration technology such as missiles, rockets, and other related equipment. Virgin Galactic Holdings serves customers in the United States.
Read more on SPCE →
